AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12932301 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice and individualized sub‐maximal exercise programs
Number of subjects: 0
Study 12932301 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10874228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 120
Study 10874228 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 120
Study 10874228 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 120
Study 10874228 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment group (Sotalol and Amiodarone combined)
Number of subjects: 120
Study 9107560 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (titrated up to 10 mg, starting with 1.25 mg daily)
Number of subjects: 2500
Study 1601837 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT)
Number of subjects: 31
Study 3516704 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (5 mg tds to 15 mg tds)
Number of subjects: 23
Study 3516704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 3516704 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 23
Study 31573615 — intervention group
Group type: EXPERIMENTAL
Intervention: FR 85% 5-14
Number of subjects: 300
Study 31573615 — intervention group
Group type: EXPERIMENTAL
Intervention: FR 85% 1-14
Number of subjects: 300
Study 31573615 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 300
Study 28993707 — intervention group
Group type: EXPERIMENTAL
Intervention: Active commuting (BIKE, n=35)
Number of subjects: 130
Study 28993707 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (MOD, n=39)
Number of subjects: 130
Study 28993707 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity exercise (VIG, n=38)
Number of subjects: 130
Study 28993707 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity exercise (VIG)
Number of subjects: 130
Study 28993707 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON, n=18)
Number of subjects: 130
Study 28065235 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan + analog traditional Chinese medicine (TA)
Number of subjects: 270
Study 28065235 — intervention group
Group type: COMPARATOR
Intervention: traditional Chinese medicine + analog telmisartan (TCMA)
Number of subjects: 270
Study 28065235 — intervention group
Group type: COMPARATOR
Intervention: telmisartan + traditional Chinese medicine (TTCM)
Number of subjects: 270
Study 28065235 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 270
Study 28065235 — intervention group
Group type: EXPERIMENTAL
Intervention: liver function and abnormal serum potassium rate
Number of subjects: 270
Study 25376415 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent lifestyle intervention
Number of subjects: 0
Study 25376415 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 22142894 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental conditions (4 groups)
Number of subjects: 243
Study 22142894 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 group)
Number of subjects: 243
Study 22142894 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 243
Study 19823111 — intervention group
Group type: EXPERIMENTAL
Intervention: SPL7013 Gel 0.5% (N = 8)
Number of subjects: 37
Study 19823111 — intervention group
Group type: EXPERIMENTAL
Intervention: SPL7013 Gel 1% (N = 8)
Number of subjects: 37
Study 19823111 — intervention group
Group type: EXPERIMENTAL
Intervention: SPL7013 Gel 3% (N = 9)
Number of subjects: 37
Study 19823111 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (N = 12)
Number of subjects: 37
Study 17094973 — intervention group
Group type: EXPERIMENTAL
Intervention: Edwards‐Wallace embryo-transfer catheter
Number of subjects: 100
Study 17094973 — intervention group
Group type: COMPARATOR
Intervention: Cook World embryo-transfer catheter
Number of subjects: 100
Study 17094973 — intervention group
Group type: EXPERIMENTAL
Intervention: Flare stimulation protocol
Number of subjects: 100
Study 15293054 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (ECC) - 50 maximal voluntary eccentric contractions at 30 degrees x s(‐1)
Number of subjects: 14
Study 15293054 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise (ISO) - 50 maximal voluntary isometric contractions at a lengthened position
Number of subjects: 14
Study 15293054 — intervention group
Group type: COMPARATOR
Intervention: Eccentric exercise (ECC)
Number of subjects: 14
Study 11672461 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ) at 10 mg/kg per day for 3 days
Number of subjects: 210
Study 11672461 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ) at 10 mg/kg per day for 3 days
Number of subjects: 210
Study 11672461 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 210
Study 11672461 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 210
Study 9828551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine hydrochloride 100 mg daily one hour before radiation therapy for 7 days
Number of subjects: 104
Study 9828551 — intervention group
Group type: COMPARATOR
Intervention: Control group (irradiation alone)
Number of subjects: 104
Study 9828551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine hydrochloride
Number of subjects: 104
Study 7735088 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management program
Number of subjects: 0
Study 2743965 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 kcal lactovegetarian diet
Number of subjects: 110
Study 2743965 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric mixed diet
Number of subjects: 110
Study 2743965 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 110
Study 30848025 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil (PR group)
Number of subjects: 99
Study 30848025 — intervention group
Group type: COMPARATOR
Intervention: Propofol (P group)
Number of subjects: 99
Study 30848025 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study 28029066 — intervention group
Group type: EXPERIMENTAL
Intervention: High load without BFR (HL) (70% VO2max)
Number of subjects: 21
Study 28029066 — intervention group
Group type: EXPERIMENTAL
Intervention: Low load with BFR (LL‐BFR) (40% VO2max + 50% BFR)
Number of subjects: 21
Study 28029066 — intervention group
Group type: COMPARATOR
Intervention: Low load without BFR (LL) (40% VO2max)
Number of subjects: 21
Study 26302024 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (cultured Lactobacillus subtilis/Streptococcus faecium) 1500 mg/day for 7 days
Number of subjects: 117
Study 26302024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 24250224 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Number of subjects: 33
Study 24250224 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing
Number of subjects: 33
Study 24250224 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 33
Study 22007715 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01
Number of subjects: 6000
Study 22007715 — intervention group
Group type: COMPARATOR
Intervention: Control (non-malaria comparator vaccine)
Number of subjects: 6000
Study 17534670 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD plus usual care
Number of subjects: 100
Study 17534670 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 17288757 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (10 microg/kg bolus i.v. followed by 0.15 microg x kg(‐1) x min(‐1) for 36 hours) administered early before PCI
Number of subjects: 158
Study 17288757 — intervention group
Group type: COMPARATOR
Intervention: Tirofiban administered late before PCI
Number of subjects: 158
Study 14723152 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (amifostinum) used during polychemotherapy
Number of subjects: 10
Study 14723152 — intervention group
Group type: COMPARATOR
Intervention: Polychemotherapy alone (Control group)
Number of subjects: 10
Study 15728061 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (bolus of 1 mg/kg and then 0.25 mg x kg(‐1) x min(‐1))
Number of subjects: 45
Study 15728061 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (bolus of 0.125 mg/kg and then 0.04 mg x kg(‐1) x min(‐1))
Number of subjects: 45
Study 15728061 — intervention group
Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 45
Study 10473886 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with acute leukemia
Number of subjects: 18
Study 10473886 — intervention group
Group type: COMPARATOR
Intervention: Patients with iron deficiency anemia (control group)
Number of subjects: 18
Study 8566840 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg terlipressin
Number of subjects: 30
Study 8566840 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms octreotide
Number of subjects: 30
Study 8566840 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 30
Study 2008946 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine sulfate (ITMS) 15 micrograms/kg
Number of subjects: 22
Study 2008946 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL) group (no actual dural puncture)
Number of subjects: 22
Study 7042252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 71
Study 7042252 — intervention group
Group type: COMPARATOR
Intervention: Propantheline (optimally effective dose)
Number of subjects: 71
Study 27154526 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute coronary angiography (CAG)
Number of subjects: 250
Study 27154526 — intervention group
Group type: COMPARATOR
Intervention: Subacute coronary angiography (CAG)
Number of subjects: 250
Study 26066615 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) implantation
Number of subjects: 44
Study 26066615 — intervention group
Group type: COMPARATOR
Intervention: Control (without ADM)
Number of subjects: 44
Study 26066615 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 24945085 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR) adjunctive to psychostimulant (1-4 mg/d)
Number of subjects: 0
Study 24945085 — intervention group
Group type: COMPARATOR
Intervention: Placebo adjunctive to psychostimulant
Number of subjects: 0
Study 22972364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (pitavastatin or atorvastatin)
Number of subjects: 242
Study 19167094 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupported online computerized cognitive behavioral therapy (CCBT)
Number of subjects: 200
Study 19167094 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy of CCBT
Number of subjects: 200
Study 17276261 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis Z9000 silicone IOL
Number of subjects: 43
Study 17276261 — intervention group
Group type: COMPARATOR
Intervention: AcrySof IQ SN60WF acrylic IOL
Number of subjects: 43
Study 15213077 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg.kg(‐1) of tranexamic acid at induction of anesthesia (Group B)
Number of subjects: 150
Study 15213077 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg.kg(‐1) at induction followed by an infusion of 1 mg.kg(‐1).h(‐1) (Group C)
Number of subjects: 150
Study 15213077 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg.kg(‐1) at induction, 10 mg.kg(‐1) on bypass, and 10 mg.kg(‐1) after protamine (Group D)
Number of subjects: 150
Study 15213077 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg.kg(‐1) at induction and again after protamine (Group E)
Number of subjects: 150
Study 15213077 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 150
Study 11210578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin + Tobramycin (CIP + T)
Number of subjects: 118
Study 11210578 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin + Placebo (CIP + P)
Number of subjects: 118
Study 9879617 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium infusions in acute myocardial infarction
Number of subjects: 0
Study 7982129 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3.5 ml saline)
Number of subjects: 8
Study 7982129 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg ANP (dissolved in 3.5 ml saline)
Number of subjects: 8
Study 7982129 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ANP (dissolved in 3.5 ml saline)
Number of subjects: 8
Study 7982129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7982129 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg ANP
Number of subjects: 8
Study 7982129 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ANP
Number of subjects: 8
Study 2660373 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (Mucomyst) administered systemically in the recommended dosage
Number of subjects: 110
Study 2660373 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 110
Study 31232957 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort care
Number of subjects: 100
Study 28252160 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiology best practices (AB)
Number of subjects: 154
Study 28252160 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer decides OTC model (CD)
Number of subjects: 154
Study 28252160 — intervention group
Group type: COMPARATOR
Intervention: Placebo devices (P)
Number of subjects: 154
Study 26490826 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based teaching
Number of subjects: 39
Study 26490826 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based teaching
Number of subjects: 39
Study 26490826 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study 24168460 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Jing-jiaji points for 30 minutes, five sessions per week for a total of 20 sessions over four weeks.
Number of subjects: 0
Study 24168460 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at Jing-jiaji points for 30 minutes, five sessions per week for a total of 20 sessions over four weeks.
Number of subjects: 0
Study 21320549 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of PCV7
Number of subjects: 684
Study 21320549 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of PCV7
Number of subjects: 684
Study 21320549 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of PCV7
Number of subjects: 684
Study 21320549 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster with PPV
Number of subjects: 684
Study 21344811 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (10 sessions, twice a week)
Number of subjects: 61
Study 21344811 — intervention group
Group type: COMPARATOR
Intervention: Night splinting (prefabricated volar neutral wrist splint during the night for 5 weeks)
Number of subjects: 61
Study 17634060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaxolone (1 mg/kg, b.i.d. to 12 mg/kg t.i.d. over 16 days, followed by 8 weeks maintenance)
Number of subjects: 15
Study 17634060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Number of subjects: 15
Study 16155694 — intervention group
Group type: EXPERIMENTAL
Intervention: High pull J hook headgear (HPHG)
Number of subjects: 60
Study 16155694 — intervention group
Group type: COMPARATOR
Intervention: Non-HPHG
Number of subjects: 60
Study 12095015 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.5 microg kg(‐1) min(‐1)
Number of subjects: 72
Study 12095015 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl bolus dose of 1.5 microg kg(‐1)
Number of subjects: 72
Study 10022407 — intervention group
Group type: COMPARATOR
Intervention: Radioiodine
Number of subjects: 110
Study 10022407 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine plus lithium
Number of subjects: 110
Study 10022407 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study 7779317 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help video for insomniacs
Number of subjects: 100
Study 7779317 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist guidance supplementing self-help video for insomniacs
Number of subjects: 100
Study 7779317 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group of senior insomniacs
Number of subjects: 100
Study 2276653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical dilatation (Group A)
Number of subjects: 60
Study 2276653 — intervention group
Group type: COMPARATOR
Intervention: No cervical dilatation (Group B)
Number of subjects: 60
Study 7440694 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg, iv) at 2300 h
Number of subjects: 26
Study 7440694 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg, iv) at 1100 h
Number of subjects: 26
Study 7440694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31384636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole hydrochloride extended-release tablet (Requip CR) at 2- to 16-mg doses
Number of subjects: 20
Study 31384636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31384636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole hydrochloride extended-release tablet (Requip CR)
Number of subjects: 20
Study 28169881 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 14684
Study 28169881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14684
Study 25904442 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg Intron (PEG‐IFNα‐2b)
Number of subjects: 60
Study 25904442 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegasys (PEG‐IFNα‐2a)
Number of subjects: 60
Study 25904442 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiveron Retard (PEG‐IFNα‐2a)
Number of subjects: 60
Study 22726906 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptable automation
Number of subjects: 40
Study 22726906 — intervention group
Group type: COMPARATOR
Intervention: Static automation (low, medium, high)
Number of subjects: 40
Study 21966817 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (20 mg, vaginally every 6 hours, maximum 3 times)
Number of subjects: 66
Study 21966817 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone (0.5 mcg, vaginally every 6 hours, maximum 3 times)
Number of subjects: 66
Study 21966817 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone (0.5 mcg)
Number of subjects: 66
Study 21966817 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (20 mg)
Number of subjects: 66
Study 21966817 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 66
Study 19375870 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive, behaviorally‐based family intervention for dual disorders program (FIDD)
Number of subjects: 2
Study 19375870 — intervention group
Group type: COMPARATOR
Intervention: Shorter‐term family psychoeducational program (FPE)
Number of subjects: 2
Study 17352450 — intervention group
Group type: EXPERIMENTAL
Intervention: Various therapeutic agents used in the management of Polycythaemia Vera
Number of subjects: 0
Study 15627052 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 11181659 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy
Number of subjects: 11
Study 11181659 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer algorithm for calculating 10-year absolute outcome data
Number of subjects: 11
Study 11181659 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison with previously described actuarial algorithm
Number of subjects: 11
Study 9240689 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCK-derived vaccine
Number of subjects: 114
Study 9240689 — intervention group
Group type: COMPARATOR
Intervention: Egg-derived vaccine
Number of subjects: 114
Study 7962681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release adinazolam
Number of subjects: 206
Study 7962681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 3296606 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 8% glucose
Number of subjects: 41
Study 3296606 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine without glucose
Number of subjects: 41
Study 3296606 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with and without glucose
Number of subjects: 41
Study 29334675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pose running retraining (three 2-h sessions)
Number of subjects: 20
Study 29334675 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 26404701 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural intervention for depression
Number of subjects: 20
Study 26404701 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 20
Study 25395284 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity inspiratory muscle training
Number of subjects: 22
Study 25395284 — intervention group
Group type: COMPARATOR
Intervention: Sham protocol (Control Group)
Number of subjects: 22
Study 21465325 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 80
Study 21465325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 20489040 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb muscle fatigue induced by sustained contractions at > or = 80% of maximal voluntary contraction
Number of subjects: 12
Study 20489040 — intervention group
Group type: COMPARATOR
Intervention: Sham protocol (no muscle fatigue)
Number of subjects: 12
Study 18537503 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based cognitive assessment
Number of subjects: 0
Study 18537503 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 0